Vitamin D3 for Life

Live Enlightened

Article

Lithocholic Acid and Alternative VDR Ligands: Evidence Synthesis

Previous related pageIntestinal VDR, Barrier Function and Microbial Metabolism: Study SummaryNext related pageLocal Vitamin D Activation, Airway Defence and Epithelial Integrity: Full Evidence Review
Study at a glance

Can anything besides active vitamin D attach to the vitamin D receptor?

Yes. Lithocholic acid, a bile acid produced by chemical processes in the gut, can attach to the receptor. Laboratory studies show that it attaches much less strongly than calcitriol, the active vitamin D hormone.

Does lithocholic acid produce the same response as active vitamin D?

No. In mice, its measured receptor response was concentrated in the lower small intestine. It did not reproduce the broader intestinal and calcium response seen with active vitamin D in the same experiments.

Does this make lithocholic acid a substitute for vitamin D?

No. Attaching to the receptor does not establish the same effects, safety or benefits in people. These experiments support a possible role within the gut, not replacement of vitamin D or proof of a major hormone role throughout the body.

Read the full article below ↓

Calcitriol is the canonical high-affinity hormonal ligand for VDR, but it is not the only endogenous chemical class that can interact with the receptor. Lithocholic acid (LCA), a secondary bile acid generated in intestinal metabolism, provides the best-developed example of an alternative VDR ligand. Binding assays, receptor structures and mouse intestinal experiments converge on a useful conclusion: VDR can recognise LCA-type molecules, but ligand recognition does not make LCA physiologically equivalent to calcitriol.

Direct binding is real, but the affinity is much lower than for calcitriol

Kollitz and colleagues compared VDRs from several vertebrate species using competitive ligand-binding and transactivation assays. LCA displaced labelled 1,25-dihydroxyvitamin D3 from all VDRs tested, with LCA inhibition constants in the micromolar range, about 4.2 to 9.5 μM across the receptors examined. The binding result establishes direct receptor affinity rather than an indirect cellular effect.

Functional activation was more context-dependent than binding. Human VDR showed a significant transcriptional response to 100 μM LCA, whereas several non-mammalian VDRs did not respond unless exogenous coregulators were supplied. The study therefore separates two properties that are often collapsed: a receptor can bind a ligand, yet the efficiency of transcriptional activation can still depend on receptor: coregulator relationships.

Structural work shows how a very different molecule fits the same pocket

Masuno and colleagues solved rat VDR ligand-binding-domain structures with LCA, 3-keto LCA, LCA acetate and LCA propionate together with a MED1 coactivator peptide. All four LCA-type ligands occupied the same VDR ligand-binding pocket used by 1,25-dihydroxyvitamin D3, but they did so in the opposite orientation.

Despite that reversed orientation, the LCA scaffolds reproduced much of the hydrophobic and hydrogen-bonding network used by the natural hormone. Their carboxyl and A-ring substituents exchanged some of the interaction roles performed by the polar groups of calcitriol. Additional contacts involving C-3 substituents differed among LCA derivatives and offered a structural explanation for differences in agonist potency. The receptor therefore has a pocket flexible enough to recognise a distinct chemical scaffold while remaining chemically selective.

The ileum provides a physiological context that binding assays cannot

Ishizawa and colleagues compared oral 1,25-dihydroxyvitamin D3 and LCA in mice. Calcitriol induced the VDR target gene Cyp24a1 broadly in the duodenum, jejunum and ileum. LCA, by contrast, had little effect on Cyp24a1 in the duodenum or jejunum but induced it strongly in the ileum, where the response could be as large as that produced by calcitriol under the tested conditions.

The downstream profile was also ligand-selective. Calcitriol increased the calcium-transporter gene Trpv6 in the upper intestine and increased plasma calcium; LCA did not. Oral LCA also failed to induce the kidney VDR target response measured in the study. Most importantly for causal interpretation, LCA did not induce ileal Cyp24a1 in VDR-null mice. The ileal response therefore required VDR rather than merely accompanying LCA exposure.

The three studies answer different parts of the ligand question

Kollitz establishes direct competitive binding and shows that binding and transactivation can diverge with receptor/coregulator context. Masuno explains how LCA-type ligands can occupy the canonical pocket despite their different chemistry. Ishizawa shows that receptor engagement can become a VDR-dependent tissue response in vivo, while simultaneously demonstrating that the response pattern differs from calcitriol across intestine and kidney.

These are complementary evidence types rather than repetitions. Biochemical affinity does not establish tissue exposure; crystallography does not establish whole-animal response; a mouse ileal response does not by itself explain the binding geometry. Their convergence is what supports an alternative-ligand model.

Why LCA is not ‘another form of vitamin D’

The authorised evidence does not support equivalence. LCA binds VDR at much lower affinity than the canonical hormone, its transactivation depends strongly on receptor and coregulator context, it occupies the pocket differently, and its demonstrated in-vivo response is preferentially intestinal rather than a copy of calcitriol’s calcium-regulatory pattern. The appropriate conclusion is ligand selectivity, not substitution.

Human physiological importance also remains bounded. The strongest tissue-response experiment is a mouse oral-ligand model, and experimental doses do not automatically reproduce ordinary human intestinal exposure. The evidence establishes a defensible VDR: LCA signalling axis and a plausible intestinal role; it does not establish that LCA is a major systemic vitamin D hormone.

For the parent receptor framework, see Vitamin D Receptors. For the structural comparison, see Vitamin D Receptor Structure and Ligand Recognition.

Primary evidence used in this synthesis

  • Evolutionary and Functional Diversification of the Vitamin D Receptor-Lithocholic Acid Partnership · PLoS One. 2016;11(12):e0168278. DOI: 10.1371/journal.pone.0168278.
  • Crystal structures of complexes of vitamin D receptor ligand-binding domain with lithocholic acid derivatives · J Lipid Res. 2013;54(8):2206 to 2213. DOI: 10.1194/jlr.M038307.
  • Lithocholic Acid Is a Vitamin D Receptor Ligand That Acts Preferentially in the Ileum · Int J Mol Sci. 2018;19(7):1975. DOI: 10.3390/ijms19071975.

Related reading

Library

The ERRα-VDR axis promotes calcitriol degradation and estrogen signaling in breast cancer cells, while VDR‐CYP24A1‐ERRα overexpression correlates with poor prognosis in patients with basal‐like breast cancer

Besides estrogen receptor alpha (ERα), estrogen‐related receptor alpha (ERRα) has also been shown to interfere with the VDR pathway, but its role in the antitumor and transactivation activity of calcitriol is completely unknown in breast cancer (BC).

Original paper ↗Read more →

Original sources